Firm dispels blood clot fears

CanSino Biologics Inc (CanSinoBIO) has said that no serious blood clot cases were reported in the recipients of its Covid-19 vaccine Ad5-nCoV.

“No blood clot-related serious adverse events have been reported in around one million vaccinations of Ad5-nCoV,” CanSinoBIO said in a statement.

The statement came after US federal health agencies on Tuesday called for a pause of the use of Johnson & Johnson’s Covid19 vaccine, which applies a similar technology to Ad5-nCoV, following some blood clots reports.